These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20198344)

  • 1. Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage.
    De Moura J; Kavalec FL; Doghman M; Rosati R; Custodio G; Lalli E; Cavallari GM; Santa Maria J; Figueiredo BC
    Int J Oncol; 2010 Apr; 36(4):983-90. PubMed ID: 20198344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective biological study in relation to a family with Li-Fraumeni syndrome.
    Aurtenetxe Sáez O; Calvo B; Fernández-Teijeiro A; Pérez P; Navajas A
    Clin Transl Oncol; 2012 May; 14(5):396-8. PubMed ID: 22551548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations.
    Barley RD; Enns L; Paterson MC; Mirzayans R
    Oncogene; 1998 Aug; 17(5):533-43. PubMed ID: 9704919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Li-Fraumeni syndrome.
    Chompret A
    Biochimie; 2002 Jan; 84(1):75-82. PubMed ID: 11900879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
    Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
    Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
    Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
    Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family.
    Güran S; Tunca Y; Imirzalioğlu N
    Cancer Genet Cytogenet; 1999 Sep; 113(2):145-51. PubMed ID: 10484981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell analysis of p16(INK4a) and p21(WAF1) expression suggests distinct mechanisms of senescence in normal human and Li-Fraumeni Syndrome fibroblasts.
    Mirzayans R; Andrais B; Scott A; Paterson MC; Murray D
    J Cell Physiol; 2010 Apr; 223(1):57-67. PubMed ID: 20039273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
    Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
    Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
    Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
    BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
    Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
    Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
    Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
    Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
    Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three germline mutations in the TP53 gene.
    Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
    Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.